A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

September 28, 2026

Study Completion Date

September 28, 2026

Conditions
Stargardt Disease
Interventions
DRUG

OCU410ST

Subretinal Administration of OCU410ST

Trial Locations (14)

16505

RECRUITING

Erie Retina Research, LLC, Erie

27710

RECRUITING

Duke Eye Center, Durham

32607

RECRUITING

Vitreo Retinal Associates, P.A., Gainesville

33064

RECRUITING

Advanced Research, LLC, Pompano Beach

33136

RECRUITING

Bascom Palmer Eye Institute, Miami

39202

RECRUITING

Mississippi Retina Associates, Jackson

46032

RECRUITING

Retina Partners Midwest, P.C., Carmel

63128

RECRUITING

The Retina Institute, St Louis

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

77401

RECRUITING

Retina Consultants of Texas, Bellaire

78503

RECRUITING

Valley Retina Institute, McAllen

85020

RECRUITING

Associated Retina Consultants, Phoenix

95825

NOT_YET_RECRUITING

Retinal Consultants Medical Group, Sacramento

02115

RECRUITING

Boston Children's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocugen

INDUSTRY